Soliris (eculizumab), an approved drug for atypical hemolytic uremic syndrome (aHUS), successfully treated a rare case of the disease in a girl, age 14 months, in China, according to a case study. After eight doses of the therapy, the levels of self-reactive antibodies against complement factor H —…
News
The kidney function of a woman with atypical hemolytic uremic syndrome (aHUS) was completely rescued with Soliris (eculizumab), but only after more than a year of treatment, a case study reports. “This case report supports the hypothesis that kidney pathological [disease] resolution in complement-mediated aHUS requires a long…
A U.S. woman with atypical hemolytic uremic syndrome (aHUS) has been in disease remission for 13 years while receiving treatment with C5 complement inhibitors after undergoing a kidney transplant, a new report details. According to the researchers, this is the longest reported case in the literature of an aHUS…
Long-term treatment with Ultomiris (ravulizumab) led to sustained clinical improvements for adults and children with atypical hemolytic uremic syndrome (aHUS), according to new two-year data from a pair of clinical trials. Patients in both age groups saw improvements in blood-related health factors and kidney function, and experienced less…
A girl in China had atypical hemolytic uremic syndrome (aHUS) and accompanying protein-losing enteropathy (PLE), a condition in which there is an excessive loss of proteins through the gastrointestinal tract. Treatment with Soliris (eculizumab) resolved both her aHUS-related kidney disease and PLE, according to a report. “Our case…
A toddler developed atypical hemolytic uremic syndrome (aHUS) while receiving chemotherapy to treat cancer, according to a case report. It’s easy for aHUS in cancer patients undergoing chemotherapy to be missed, since its symptoms are often mistakenly assumed to be complications caused by cancer or treatment, said the…
A woman developed atypical hemolytic uremic syndrome (aHUS) after receiving the first dose of a COVID-19 vaccine, according to a case study from Brazil. The researchers said the “connection of symptoms post-COVID-19 vaccination to aHUS … emphasizes the need for ongoing monitoring and research into vaccine-related complications.” The case…
The U.S. Food and Drug Administration (FDA) has approved Epysqli (eculizumab-aagh), a biosimilar to Soliris (eculizumab), as an atypical hemolytic uremic syndrome (aHUS) treatment. Epysqli, from Samsung Bioepis, has also been approved to treat people with paroxysmal nocturnal hemoglobinuria (PNH), a rare disease that, like aHUS,…
The use of Soliris (eculizumab) is changing the natural course of atypical hemolytic uremic syndrome (aHUS) in Latin America as it has in other regions, helping many patients achieve better outcomes, according to a review study. While aHUS arises from the same genetic causes and manifests in a…
A woman in her 60s developed atypical hemolytic uremic syndrome (aHUS) as a result of severe babesiosis, a tick-borne parasitic infection, according to a recent U.S. case report. Babesiosis is caused by a parasite that infects red blood cells. The disease is transmitted from the bite of an infected tick…
Recent Posts
- Plasma exchange helps child with treatment-resistant aHUS
- The big bruise I failed to pay attention to turned out to be a blood clot
- Nurses lead care team to heal aHUS baby’s severe skin wounds
- Blood disease helps trigger aHUS after childbirth in woman in rare case
- No answers about what’s causing severe inflammation and swelling
- Approved treatment helps girl recover from severe aHUS, report shows
- Blood protein may help track disease activity in people with aHUS
- Just along for the ride on the roller coaster of life with chronic illness
- Developing aHUS complicates baby’s HUS recovery, but drug helps
- Sequential MS treatments trigger aHUS in woman: Case study